«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 13

Page:

2541-2545

Research Field:

Publishing date:

Info

Title:

Research progress on abnormal DNA methylation in the occurrence,development,diagnosis and treatment of prostate cancer

Author(s):

GU Jun; CHEN Zhenjie; HE Zexi; WANG Haifeng; WU Haichao; LIN Jiawei; DING Mingxia

Department of Urology£¬the Second Affiliated Hospital of Kunming Medical University£¬Yunnan Institute of Urology£¬Yunnan Kunming 650101£¬China.

Keywords:

DNA methylation; epigenetics; prostate cancer; diagnosis; treatment

PACS:

R737.25

DOI:

10.3969/j.issn.1672-4992.2023.13.033

Abstract:

Prostate cancer is one of the most common men malignant tumor in the world.Recent studies have found that the occurrence and development of prostate cancer is largely driven by epigenetic modifications,among which the most important is abnormal DNA methylation.Abnormal methylation of DNA promoters can lead to abnormal gene expression and regulate the development of prostate cancer.In addition,the diagnosis of prostate cancer still relies on invasive needle biopsy of prostate now,while non-invasive liquid biopsy based on abnormal DNA methylation is expected to become the development trend of molecular diagnosis of prostate cancer in the future.It also provides a new therapeutic target for prostate cancer.In this article,we review the research progress of DNA methylation in the development,progression,early diagnosis,prognostic evaluation and treatment of prostate cancer.

References:

£Û1£ÝSUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries £ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£ÝSVENSSON E,CHRISTIANSEN CF,ULRICHSEN SP,et al.Survival after bone metastasis by primary cancer type:a Danish population-based cohort study £ÛJ£Ý.BMJ Open,2017,7(9):e016022.
£Û3£ÝVAN DEN BERGH RC,VAN CASTEREN NJ,VAN DEN BROECK T,et al.Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment:a systematic review £ÛJ£Ý.Eur Urol,2016,69(5):802-820.
£Û4£ÝSUGIURA M,SATO H,KANESAKA M,et al.Epigenetic modifications in prostate cancer £ÛJ£Ý.Int J Urol,2021,28(2):140-149.
£Û5£ÝLIU Q,LIU G,MARTIN DT,et al.Genome-wide association analysis reveals regulation of at-risk loci by DNA methylation in prostate cancer £ÛJ£Ý.Asian J Androl,2021,23(5):472-478.
£Û6£ÝXU N,WU YP,KE ZB,et al.Identification of key DNA methylation-driven genes in prostate adenocarcinoma:an integrative analysis of TCGA methylation data £ÛJ£Ý.J Transl Med,2019,17(1):311.
£Û7£ÝZHAO SG,CHEN WS,LI H,et al.The DNA methylation landscape of advanced prostate cancer £ÛJ£Ý.Nat Genet,2020,52(8):778-789.
£Û8£ÝLI J,XU C,LEE HJ,et al.A genomic and epigenomic atlas of prostate cancer in Asian populations £ÛJ£Ý.Nature,2020,580(7801):93-99.
£Û9£ÝPELLACANI D,DROOP AP,FRAME FM,et al.Phenotype-independent DNA methylation changes in prostate cancer £ÛJ£Ý.Br J Cancer,2018,119(9):1133-1143.
£Û10£ÝYANG X,WANG S,REHEMAN A.Regulation of RUNX3 expression by DNA methylation in prostate cancer £ÛJ£Ý.Cancer Manag Res,2020,12:6411-6420.
£Û11£ÝCHEN J,HUANG L,ZHU Q,et al.MTSS1 hypermethylation is associated with prostate cancer progression £ÛJ£Ý.J Cell Physiol,2020,235(3):2687-2697.
£Û12£ÝLI H,KIM C,LIU W,et al.Olfactomedin 4 downregulation is associated with tumor initiation,growth and progression in human prostate cancer £ÛJ£Ý.Int J Cancer,2020,146(5):1346-1358.
£Û13£ÝGAO X,DAI C,HUANG S,et al.Functional silencing of HSD17B2 in prostate cancer promotes disease progression £ÛJ£Ý.Clin Cancer Res,2019,25(4):1291-1301.
£Û14£ÝLENG X,LIU M,TAO D,et al.Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells £ÛJ£Ý.Cancer Sci,2021,112(2):691-702.
£Û15£ÝMAZZU YZ,YOSHIKAWA Y,NANDAKUMAR S,et al.Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer £ÛJ£Ý.Mol Oncol,2019,13(9):1944-1958.
£Û16£ÝSHI XB,XUE L,MA AH,et al.Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells £ÛJ£Ý.Oncogene,2013,32(35):4130-4138.
£Û17£ÝBHATIA V,YADAV A,TIWARI R,et al.Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer £ÛJ£Ý.Clin Cancer Res,2019,25(9):2755-2768.
£Û18£ÝMOTTAHEDEH J,HAFFNER MC,GROGAN TR,et al.CD38 is methylated in prostate cancer and regulates extracellular NAD £ÛJ£Ý.Cancer Metab,2018,6(1):13.
£Û19£ÝHAN R,HENSLEY PJ,LI J,et al.Integrin-associated CD151 is a suppressor of prostate cancer progression £ÛJ£Ý.Am J Transl Res,2020,12(4):1428-1442.
£Û20£ÝTOLKACH Y,ZARBL R,BAUER S,et al.DNA promoter methylation and ERG regulate the expression of CD24 in prostate cancer £ÛJ£Ý.Am J Pathol,2021,191(4):618-630.
£Û21£ÝYAO L,REN S,ZHANG M,et al.Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer £ÛJ£Ý.Oncotarget,2015,6(38):40611-40621.
£Û22£ÝLI Y,MENG L,SHI T,et al.Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer £ÛJ£Ý.Cell Biol Int,2021,45(1):117-126.
£Û23£ÝLAN T,YIN L,ZHANG H,et al.Diagnostic value of DACT-2 methylation in serum of prostate cancer patients £ÛJ£Ý.Ann Palliat Med,2021,10(3):2421-2428.
£Û24£ÝBRAIT M,BANERJEE M,MALDONADO L,et al.Promoter methylation of MCAM,ER¦Á and ER¦Â in serum of early stage prostate cancer patients £ÛJ£Ý.Oncotarget,2017,8(9):15431-15440.
£Û25£ÝHALDRUP C,PEDERSEN AL,OGAARD N,et al.Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies £ÛJ£Ý.Mol Oncol,2018,12(4):545-560.
£Û26£ÝCONST¦ENCIO V,NUNES SP,MOREIRA-BARBOSA C,et al.Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel £ÛJ£Ý.Clin Epigenetics,2019,11(1):175.
£Û27£ÝS¦BNCHEZ BE,AGUAYO A,MART¦PNEZ B,et al.Using genetic and epigenetic markers to improve differential diagnosis of prostate cancer and benign prostatic hyperplasia by noninvasive methods in mexican patients £ÛJ£Ý.Clin Genitourin Cancer,2018,16(4):e867-e877.
£Û28£ÝREIS IM,RAMACHANDRAN K,SPEER C,et al.Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease £ÛJ£Ý.British Journal of Cancer,2015,113(3):460-468.
£Û29£ÝWANG L,LIN YL,LI B,et al.Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer £ÛJ£Ý.J Int Med Res,2014,42(5):1085-1092.
£Û30£ÝGAO X,LI LY,RASSLER J,et al.Prospective study of CRMP4 promoter methylation in prostate biopsies as a predictor for lymph node metastases £ÛJ£Ý.J Natl Cancer Inst,2017,109(6):djw282.
£Û31£ÝZHANG E,SHIORI F,MU OY,et al.Establishment of novel DNA methylation-based prostate cancer subtypes and a risk-predicting eight-gene signature £ÛJ£Ý.Front Cell Dev Biol,2021,9:639615.
£Û32£ÝGOLTZ D,HOLMES EE,GEVENSLEBEN H,et al.CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients £ÛJ£Ý.Oncotarget,2016,7(33):53309-53320.
£Û33£ÝN¢hRGAARD M,HALDRUP C,BJERRE MT,et al.Epigenetic silencing of MEIS2 in prostate cancer recurrence £ÛJ£Ý.Clin Epigenetics,2019,11(1):147.
£Û34£ÝHOLMES EE,GOLTZ D,SAILER V,et al.PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy £ÛJ£Ý.Clin Epigenetics,2016,8(1):104.
£Û35£ÝWANG X,GAO H,REN L,et al.Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer £ÛJ£Ý.BMC Cancer,2014,14(1):308.
£Û36£ÝLYNCH SM,O' NEILL KM,MCKENNA MM,et al.Regulation of miR-200c and miR-141 by methylation in prostate cancer £ÛJ£Ý.Prostate,2016,76(13):1146-1159.
£Û37£ÝFANG X,ZHENG C,LIU Z,et al.Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2'-deoxycytidine £ÛJ£Ý.Oncol Rep,2004,12(3):523-526.
£Û38£ÝRAMACHANDRAN K,SPEER C,NATHANSON L,et al.Role of DNA methylation in cabazitaxel resistance in prostate cancer £ÛJ£Ý.Anticancer Res,2016,36(1):161-168.
£Û39£ÝKUMAR SR,BRYAN JN,ESEBUA M,et al.Testis specific Y-like 5:gene expression,methylation and implications for drug sensitivity in prostate carcinoma £ÛJ£Ý.BMC Cancer,2017,17(1):158.
£Û40£ÝSONPAVDE G,APARICIO AM,ZHAN F,et al.Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer £ÛJ£Ý.Urol Oncol,2011,29(6):682-689.
£Û41£ÝTHIBAULT A,FIGG WD,BERGAN RC,et al.A phase II study of 5-aza-2' deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer £ÛJ£Ý.Tumori,1998,84(1):87-89.
£Û42£ÝSINGAL R,RAMACHANDRAN K,GORDIAN E,et al.Phase I/II study of azacitidine,docetaxel,and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy £ÛJ£Ý.Clin Genitourin Cancer,2015,13(1):22-31.

Memo

Memo:

ÔÆÄÏÊ¡Ó¦Óûù´¡Ñо¿-À¥Ò½ÁªºÏרÏî£Û±àºÅ£º2019FE001(-226)£Ý;ÔÆÄÏÊ¡¸ßУ´´ÐÂÍŶӽ¨ÉèÏîÄ¿(±àºÅ£ºÔƽ̡²2019¡³58ºÅ);ÔÆÄÏÊ¡¡°ÍòÈ˼ƻ®¡±ÃûҽרÏî¡¢ÔÆÄÏÊ¡Áì¾üÈ˲ÅÅàÑøÏîÄ¿£¨±àºÅ£ºL-2018009£©

Common functions

Last Update: 2023-05-31